Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amyotrophic Lateral Sclerosis
CytRx's Arimoclomol meets primary safety and tolerability endpoints in Phase IIa ALS clinical trial
October 25th, 2006
CytRx Corporation (CYTR) announced that its lead drug candidate arimoclomol was shown to be safe and well tolerated at all three doses tested in its Phase IIa clinical trial in patients with amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease). In the 10-center, double-blind, placebo-controlled Phase IIa trial, ALS patients received placebo or arimoclomol in one of three dose levels (25 mg, 50 mg or 100 mg) three times daily for 12 weeks and then were studied for an additional four weeks without treatment. Eighty-four patients with ALS entered the clinical trial with only seven withdrawing prior to completion of dosing. No statistically significant...
Source: Biotech Week (2006-10-25)
|
